Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Date
2021
Author
Dvorkin, Mikhail
Hochmair, Maximilian J.
ÖZGÜROĞLU, Mustafa
Ji, Jun Ho
Garassino, Marina Chiara
Voitko, Oleksandr
Poltoratskiy, Artem
Ponce, Santiago
Verderame, Francesco
Havel, Libor
Bondarenko, Igor
Kazarnowicz, Andrzej
Losonczy, Gyorgy
Conev, Nikolay V.
Armstrong, Jon
Byrne, Natalie
Thiyagarajah, Piruntha
Jiang, Haiyi
Paz-Ares, Luis
Trukhin, Dmytro
Hotta, Katsuyuki
Statsenko, Galina
Reinmuth, Niels
Chen, Yuanbin
Goldman, Jonathan W.
Metadata
Show full item record
Abstract
Background First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage smallcell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone.
URI
http://hdl.handle.net/20.500.12627/1720
https://doi.org/10.1016/s1470-2045(20)30539-8
Collections